Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) FCF Margin (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of FCF Margin data on record, last reported at 241.39% in Q4 2025.

  • For Q4 2025, FCF Margin rose 63873.0% year-over-year to 241.39%; the TTM value through Dec 2025 reached 278.72%, up 16953.0%, while the annual FY2025 figure was 278.72%, 16953.0% up from the prior year.
  • FCF Margin reached 241.39% in Q4 2025 per FHTX's latest filing, down from 231.33% in the prior quarter.
  • Across five years, FCF Margin topped out at 6920.79% in Q1 2022 and bottomed at 50565.85% in Q3 2021.
  • Average FCF Margin over 5 years is 3223.81%, with a median of 430.29% recorded in 2025.
  • Peak YoY movement for FCF Margin: plummeted -4905803bps in 2021, then surged 5025961bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 1655.26% in 2021, then crashed by -142bps to 697.73% in 2022, then soared by 34bps to 457.43% in 2023, then tumbled by -92bps to 880.11% in 2024, then surged by 73bps to 241.39% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 241.39% in Q4 2025, 231.33% in Q3 2025, and 277.52% in Q2 2025.